Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007981 | 1.00 | CCR5 (0.47) | CCR5KCNH2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL13250365 | 1.00 | CCR5 (0.47) | CCR5KCNH2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL15601035 | 0.93 | — | — | |
| SCHEMBL2262923 | 0.93 | — | — | |
| SCHEMBL9938147 | 0.93 | — | — | |
| SCHEMBL5241187 | 0.93 | CCR5 (0.41) | CCR5KCNH2SLC6A1SLC6A11SLC6A13 | |
| SCHEMBL2262928 | 0.93 | — | — | |
| SCHEMBL1830086 | 0.93 | — | — | |
| SCHEMBL17006846 | 0.93 | — | — | |
| SCHEMBL474266 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250129078-A1 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-04-24 | — | — | US | claimed |
| WO-2024215809-A2 | ERBB2 INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| EP-3660069-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2024-01-03 | — | — | EP | claimed |
| EP-3569630-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2022-08-03 | — | — | EP | claimed |
| EP-3569629-B1 | FAST CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2022-07-06 | — | — | EP | claimed |
| CN-111234182-A | Fast curing epoxy system | 赢创运营有限公司 | 2020-06-05 | — | — | CN | claimed |
| US-20200172723-A1 | FAST-CURING EPOXY SYSTEMS | EVONIK OPERATIONS GMBH (DE) | 2020-06-04 | — | — | US | claimed |
| EP-3660069-A1 | FAST CURING EPOXY SYSTEMS | Evonik Operations GmbH (DE) | 2020-06-03 | — | — | EP | claimed |
| CN-110498905-A | Expediting setting type epoxy systems | EVONIK DEGUSSA GMBH | 2019-11-26 | — | — | CN | claimed |
| CN-110498904-A | Expediting setting type epoxy systems | EVONIK DEGUSSA GMBH | 2019-11-26 | — | — | CN | claimed |
| US-20190352449-A1 | FAST-CURING EPOXY SYSTEMS | EVONIK DEGUSSA GMBH (DE) | 2019-11-21 | — | — | US | claimed |
| US-20190352452-A1 | FAST-CURING EPOXY SYSTEMS | EVONIK DEGUSSA GMBH (DE) | 2019-11-21 | — | — | US | claimed |
| EP-3569630-A1 | FAST CURING EPOXY SYSTEMS | Evonik Degussa GmbH (DE) | 2019-11-20 | — | — | EP | claimed |
| EP-3569629-A1 | FAST CURING EPOXY SYSTEMS | Evonik Degussa GmbH (DE) | 2019-11-20 | — | — | EP | claimed |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | CCR5 3272/4885KCNH2 4299/4885SLC6A1 4849/4885 |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | PTPN6, PTPN1, PTPN11 | CCR5 725/4885KCNH2 4210/4885SLC6A1 1794/4885 |
| US-20250129078-A1 | ERBB2 INHIBITORS | ERBB2, ERBB3, EGFR | CCR5 1135/4885KCNH2 3531/4885SLC6A1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.